financetom
Business
financetom
/
Business
/
Geron's Q4 Net Loss Narrows, Revenue Rises
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Geron's Q4 Net Loss Narrows, Revenue Rises
Feb 26, 2025 5:25 AM

07:58 AM EST, 02/26/2025 (MT Newswires) -- Geron ( GERN ) reported Wednesday it narrowed its Q4 net loss to $0.04 per diluted share from $0.09 per share a year earlier.

Analysts polled by FactSet expected a loss of $0.02 per share.

Revenue for the quarter ended Dec. 31 was $47.5 million, up from $23,000 a year earlier.

One analyst surveyed by FactSet expected $47.5 million.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Biogen's Postnatal Depression Drug Zuranolone Gets UK Approval
Biogen's Postnatal Depression Drug Zuranolone Gets UK Approval
Aug 27, 2025
12:28 PM EDT, 08/27/2025 (MT Newswires) -- Biogen's (BIIB) zuranolone oral treatment for moderate or severe postnatal depression was approved by the United Kingdom's Medicines and Healthcare products Regulatory Agency, the medical regulator said Wednesday. Zuranolone will be available as a capsule and can be taken orally, at night with a fat-containing meal for 14 days, MHRA said. Side effects...
Amylyx Halts Rare Brain Disorder Drug Program After Disappointing Trial
Amylyx Halts Rare Brain Disorder Drug Program After Disappointing Trial
Aug 27, 2025
Amylyx Pharmaceuticals, Inc. ( AMLX ) on Wednesday decided to discontinue the ORION program of AMX0035 (sodium phenylbutyrate [PB] and taurursodiol [TURSO, also known as ursodoxicoltaurine]) in adults living with progressive supranuclear palsy (PSP). PSP is a rare, degenerative brain disorder causing issues with balance, movement, eye movements, speech, swallowing, mood, and cognition. AMX0035 did not show differences compared to...
Amylyx Halts Rare Brain Disorder Drug Program After Disappointing Trial
Amylyx Halts Rare Brain Disorder Drug Program After Disappointing Trial
Aug 27, 2025
Amylyx Pharmaceuticals, Inc. ( AMLX ) on Wednesday decided to discontinue the ORION program of AMX0035 (sodium phenylbutyrate [PB] and taurursodiol [TURSO, also known as ursodoxicoltaurine]) in adults living with progressive supranuclear palsy (PSP). PSP is a rare, degenerative brain disorder causing issues with balance, movement, eye movements, speech, swallowing, mood, and cognition. AMX0035 did not show differences compared to...
Delta to pay $78.75 million to resolve fuel dump lawsuit
Delta to pay $78.75 million to resolve fuel dump lawsuit
Aug 27, 2025
(Reuters) -Delta Air Lines agreed to pay $78.75 million to resolve a class action lawsuit over a 2020 fuel dump that doused tens of thousands of properties, including homes and schools, in Los Angeles and Orange counties in California. A proposed preliminary settlement was filed this week in Los Angeles federal court, and requires a judge's approval. The case stemmed...
Copyright 2023-2026 - www.financetom.com All Rights Reserved